New device study: Promus Element v. Xience Prime
Boston Scientific Corp. (NYSE:BSX) set out to compare its new Promus Element drug-eluting stent system with Abbott’s (ABT) Xience Prime. The BSX-funded study will evaluate coronary revascularization outcomes in a 2,980-patient sample across 50 sites in France, Germany, Italy, Spain and the U.K. Former iterations of the Promus line were private-label versions of Abbott’s Xience V drug-eluting stents, but […]